November 3rd, 2026 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that VIVALDI, a Phase Ib pilot study sponsored by CETLAM — Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplásicas, has been authorized in Spain. The study will evaluate iadademstat in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia (ND-AML) belongin

Financing led by Hatteras Venture Partners, with participation from foundational investors Lumira Ventures and adMare BioInnovations and a new syndicate of life sciences investors Proceeds will be used to advance lead Dualase® therapeutic candidate through initial clinical biomarker proof-of-concept in patients with C9ORF72-associated ALS Gene-editing platform designed to precisely remove disease-causing DNA repeat expansions, with potential applications across more than 40 repeat expansion diso

GLORIA Study Team Receives the 2026 German University Medicine Prize for Its Glioblastoma Research with CXCL12 Inhibitor NOX-A12 Researchers from six German university medical centers have received the 2026 German University Medicine Prize for their work in the GLORIA study GLORIA, TME Pharma’s Phase 1/2 study, evaluates NOX-A12 in combination with radiotherapy in newly diagnosed glioblastoma patients who are resistant to chemotherapy. In an expansion cohort, NOX-A12 and radiotherapy were also c

Edison Scientific announced an agreement to deploy the Edison AI Platform and Kosmos, Edison's AI scientist, across Pfizer’s biopharmaceutical research and development pipeline. The collaboration brings together Edison’s industry-leading AI capabilities with Pfizer’s scientific expertise and robust repositories of data across oncology, internal medicine, immunology, and more. Kosmos will access Pfizer’s data to support Pfizer’s scientists, inform critical decisions in R&D, and help accelerate th

Oct. 30, 2026 -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in the Phase 1 trial of ICP-B161, a bispecific antibody targeting TL1A and IL-23p19, for the potential treatment of autoimmune diseases, including inflammatory bowel disease (IBD). With its novel molecular design, ICP-B161 delivers an extended half-life, which allows for less frequent d

Company created following Jazz Pharmaceuticals’ acquisition of Actio Biosciences Setara plans to advance clinical-stage small molecule TRPV4 inhibitor for treatment of Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder, along with other early-stage discovery programs Investor syndicate comprised of leading healthcare investors including Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, and Regeneron Ventures, as well as Jazz Pharmaceuticals Setara Bioscienc

- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia - Oct. 30, 2026 -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib) has been recognized as the Best Product for Rare/Orphan Diseases of 2026 by The Galien Foundation. The Galien Foundation fosters, recognizes, and r

INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgery VOCERYQ™ is a plasmid DNA-based immunotherapy that targets the root cause of RRP: HPV-6 and HPV-11 INOVIO expects to make VOCERYQ available to order and ship in approximately 60 days, with full commercial launch in the first quarter of 2027 VOCERYQ represents the first U.S. FDA approved DNA medicine, validating INOVIO's novel platform

DEBRA Research and Topadur Pharma have announced a collaboration to explore a new treatment approach for dystrophic epidermolysis bullosa (DEB). DEB is one of the more severe forms of EB, characterised by extremely fragile skin and progressive, debilitating complications. The programme will evaluate Topadur’s clinical-stage compound TOP-N53 together with additional selected small molecules from its proprietary DualTOP platform. The compounds will be investigated in in vitro and in vivo models ad

The Phase III AIRWARD™ trial was published today on ClinicalTrials.gov (NCT07907991).1 AIRWARD will evaluate the efficacy and safety of verducatib, an investigational oral therapy for COPD.1 The Phase III trial will enroll adults with symptomatic COPD who continue to experience exacerbations and have blood eosinophil counts below 300 cells/µL.1 Boehringer Ingelheim today announced the registration of the Phase III AIRWARD™ trial evaluating its investigational oral therapy verducatib as a treatm